However, looking at the clinical perspective, since approximately 70% of SCN patients with AML harbor additional mutations in the RUNX1 gene, patients with SCN who are positive for CSF3R and/or RUNX1 mutation should be also transplanted to minimize the risk of MDS/AML occurrence. This evidence concerns the gene RUNX1 and myelodysplastic syndrome.